Edition:
United States

Mast Therapeutics Inc (MSTX.A)

MSTX.A on American Stock Exchange

0.12USD
2:54pm EDT
Change (% chg)

$0.00 (+1.49%)
Prev Close
$0.11
Open
$0.12
Day's High
$0.12
Day's Low
$0.12
Volume
214,414
Avg. Vol
553,622
52-wk High
$0.70
52-wk Low
$0.07

Latest Key Developments (Source: Significant Developments)

Mast Therapeutics Q4 loss per share $0.02
Monday, 6 Mar 2017 04:30pm EST 

Mast Therapeutics Inc : Mast Therapeutics reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.02 .Q4 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.  Full Article

Mast Therapeutics provides update on strategic direction
Monday, 21 Nov 2016 08:00am EST 

Mast Therapeutics Inc : Mast Therapeutics Inc - received several written indications of interest from privately-held companies for reverse merger transactions . Mast Therapeutics Inc - actively evaluating reverse merger opportunities . Mast Therapeutics Inc - will continue to explore ways to strategically monetize its vepoloxamer assets .Mast Therapeutics provides update on strategic direction.  Full Article

Mast Therapeutics committed to a reduction in workforce of four positions
Monday, 31 Oct 2016 05:22pm EDT 

Mast Therapeutics Inc : Mast Therapeutics Inc - Committed to a reduction in workforce of four positions . Mast Therapeutics Inc - Since beginning of October 2016, company's workforce has been reduced by ten employees, or approximately 38% .Mast Therapeutics Inc - Plans to implement additional cost control measures in Q4 of 2016 to further reduce its expenditures.  Full Article

Mast Therapeutics provides business update
Monday, 26 Sep 2016 09:00am EDT 

Mast Therapeutics Inc : Mast Therapeutics provides business update . Company has begun to wind down its vepoloxamer programs in sickle cell disease and heart failure . Company is planning to initiate a process to evaluate partnership opportunities for its assets . Co to make $10 million prepayment on debt facility triggered by recently announced results of phase 3 study of vepoloxamer in early Oct 2016 . Expects wind down activities will be completed in Q4 of 2016 .Company estimates that its operating expenses for 2017 will be in range of $9 to $10 million.  Full Article

Mast Therapeutics Q2 loss per share $0.05
Tuesday, 9 Aug 2016 08:00am EDT 

Mast Therapeutics Inc : Q2 loss per share $0.05 . Mast therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Mast Therapeutics receives notice of allowance of composition of matter patent application
Wednesday, 8 Jun 2016 04:05pm EDT 

Mast Therapeutics Inc : Mast Therapeutics receives notice of allowance of composition of matter patent application covering vepoloxamer . Patent is expected to expire no earlier than July 2035 . Also has filed corresponding patent applications that will allow co to seek similar patent protection for vepoloxamer in key markets .Notice of allowance concludes substantive examination of patent application.  Full Article

Mast Therapeutics says updated timing for data from Vepoloxamer study
Monday, 6 Jun 2016 05:25pm EDT 

Mast Therapeutics Inc : Updated anticipated timing for announcement of top-line data from phase 3 clinical study of Vepoloxamer in patients with sickle cell disease .Delay does not reflect on quality or integrity of results or conduct of study.  Full Article

Mast Therapeutics reports Q1 loss per share of $0.06
Friday, 6 May 2016 08:35am EDT 

Mast Therapeutics Inc : Mast therapeutics reports first quarter 2016 financial results and recent highlights . Q1 loss per share $0.06 .Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Mast Therapeutics announces pricing of underwritten public offering
Wednesday, 10 Feb 2016 09:11am EST 

Mast Therapeutics Inc:Says public offering of 29,090,910 units at a price to the public of $0.275 per unit.Each unit consists of one share of the Company's common stock and one warrant to purchase one share of the Company's common stock at an exercise price of $0.42 per share.  Full Article

Mast Therapeutics Inc announces positive top-line results from phase 2a Study Of AIR001
Monday, 1 Feb 2016 07:30am EST 

Mast Therapeutics Inc:Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic.Study met its primary endpoint; AIR001 was generally well-tolerated, with no treatment-related serious adverse events.  Full Article

More From Around the Web

BRIEF-Mast Therapeutics Q4 loss per share $0.02

* Mast Therapeutics reports fourth quarter and full year 2016 financial results